Global KRAS Inhibitor Market Analysis and Forecast 2025-2031

Summary

According to APO Research, The global KRAS Inhibitor market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for KRAS Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for KRAS Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for KRAS Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for KRAS Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of KRAS Inhibitor include Novartis, Jemincare, Amgen, Mirati Therapeutics, Innovent Biologics, Incyte, Erasca, Cardiff Oncology and BridgeBio Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for KRAS Inhibitor, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of KRAS Inhibitor, also provides the sales of main regions and countries. Of the upcoming market potential for KRAS Inhibitor, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the KRAS Inhibitor sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global KRAS Inhibitor market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for KRAS Inhibitor sales, projected growth trends, production technology, application and end-user industry.


KRAS Inhibitor Segment by Company

Novartis
Jemincare
Amgen
Mirati Therapeutics
Innovent Biologics
Incyte
Erasca
Cardiff Oncology
BridgeBio Pharma
Boehringer Ingelheim

KRAS Inhibitor Segment by Type

Lung Cancer
Colorectal Cancer
Pancreatic Cancer
Others

KRAS Inhibitor Segment by Application

Clinic Laboratories
Hospitals
Cancer Diagnostic Centres
Others

KRAS Inhibitor Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global KRAS Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of KRAS Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of KRAS Inhibitor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of KRAS Inhibitor in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of KRAS Inhibitor manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, KRAS Inhibitor sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 KRAS Inhibitor Market by Type
1.2.1 Global KRAS Inhibitor Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Lung Cancer
1.2.3 Colorectal Cancer
1.2.4 Pancreatic Cancer
1.2.5 Others
1.3 KRAS Inhibitor Market by Application
1.3.1 Global KRAS Inhibitor Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Clinic Laboratories
1.3.3 Hospitals
1.3.4 Cancer Diagnostic Centres
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 KRAS Inhibitor Market Dynamics
2.1 KRAS Inhibitor Industry Trends
2.2 KRAS Inhibitor Industry Drivers
2.3 KRAS Inhibitor Industry Opportunities and Challenges
2.4 KRAS Inhibitor Industry Restraints
3 Global Market Growth Prospects
3.1 Global KRAS Inhibitor Revenue Estimates and Forecasts (2020-2031)
3.2 Global KRAS Inhibitor Revenue by Region
3.2.1 Global KRAS Inhibitor Revenue by Region: 2020 VS 2024 VS 2031
3.2.2 Global KRAS Inhibitor Revenue by Region (2020-2025)
3.2.3 Global KRAS Inhibitor Revenue by Region (2026-2031)
3.2.4 Global KRAS Inhibitor Revenue Market Share by Region (2020-2031)
3.3 Global KRAS Inhibitor Sales Estimates and Forecasts 2020-2031
3.4 Global KRAS Inhibitor Sales by Region
3.4.1 Global KRAS Inhibitor Sales by Region: 2020 VS 2024 VS 2031
3.4.2 Global KRAS Inhibitor Sales by Region (2020-2025)
3.4.3 Global KRAS Inhibitor Sales by Region (2026-2031)
3.4.4 Global KRAS Inhibitor Sales Market Share by Region (2020-2031)
3.5 US & Canada & Mexico
3.6 Europe
3.7 China
3.8 Asia (Excluding China)
3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
4.1 Global KRAS Inhibitor Revenue by Manufacturers
4.1.1 Global KRAS Inhibitor Revenue by Manufacturers (2020-2025)
4.1.2 Global KRAS Inhibitor Revenue Market Share by Manufacturers (2020-2025)
4.1.3 Global KRAS Inhibitor Manufacturers Revenue Share Top 10 and Top 5 in 2024
4.2 Global KRAS Inhibitor Sales by Manufacturers
4.2.1 Global KRAS Inhibitor Sales by Manufacturers (2020-2025)
4.2.2 Global KRAS Inhibitor Sales Market Share by Manufacturers (2020-2025)
4.2.3 Global KRAS Inhibitor Manufacturers Sales Share Top 10 and Top 5 in 2024
4.3 Global KRAS Inhibitor Sales Price by Manufacturers (2020-2025)
4.4 Global KRAS Inhibitor Key Manufacturers Ranking, 2023 VS 2024 VS 2025
4.5 Global KRAS Inhibitor Key Manufacturers Manufacturing Sites & Headquarters
4.6 Global KRAS Inhibitor Manufacturers, Product Type & Application
4.7 Global KRAS Inhibitor Manufacturers' Establishment Date
4.8 Market Competitive Analysis
4.8.1 Global KRAS Inhibitor Market CR5 and HHI
4.8.2 2024 KRAS Inhibitor Tier 1, Tier 2, and Tier 3
5 KRAS Inhibitor Market by Type
5.1 Global KRAS Inhibitor Revenue by Type
5.1.1 Global KRAS Inhibitor Revenue by Type (2020 VS 2024 VS 2031)
5.1.2 Global KRAS Inhibitor Revenue by Type (2020-2031) & (US$ Million)
5.1.3 Global KRAS Inhibitor Revenue Market Share by Type (2020-2031)
5.2 Global KRAS Inhibitor Sales by Type
5.2.1 Global KRAS Inhibitor Sales by Type (2020 VS 2024 VS 2031)
5.2.2 Global KRAS Inhibitor Sales by Type (2020-2031) & (K Units)
5.2.3 Global KRAS Inhibitor Sales Market Share by Type (2020-2031)
5.3 Global KRAS Inhibitor Price by Type
6 KRAS Inhibitor Market by Application
6.1 Global KRAS Inhibitor Revenue by Application
6.1.1 Global KRAS Inhibitor Revenue by Application (2020 VS 2024 VS 2031)
6.1.2 Global KRAS Inhibitor Revenue by Application (2020-2031) & (US$ Million)
6.1.3 Global KRAS Inhibitor Revenue Market Share by Application (2020-2031)
6.2 Global KRAS Inhibitor Sales by Application
6.2.1 Global KRAS Inhibitor Sales by Application (2020 VS 2024 VS 2031)
6.2.2 Global KRAS Inhibitor Sales by Application (2020-2031) & (K Units)
6.2.3 Global KRAS Inhibitor Sales Market Share by Application (2020-2031)
6.3 Global KRAS Inhibitor Price by Application
7 Company Profiles
7.1 Novartis
7.1.1 Novartis Comapny Information
7.1.2 Novartis Business Overview
7.1.3 Novartis KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Novartis KRAS Inhibitor Product Portfolio
7.1.5 Novartis Recent Developments
7.2 Jemincare
7.2.1 Jemincare Comapny Information
7.2.2 Jemincare Business Overview
7.2.3 Jemincare KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Jemincare KRAS Inhibitor Product Portfolio
7.2.5 Jemincare Recent Developments
7.3 Amgen
7.3.1 Amgen Comapny Information
7.3.2 Amgen Business Overview
7.3.3 Amgen KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Amgen KRAS Inhibitor Product Portfolio
7.3.5 Amgen Recent Developments
7.4 Mirati Therapeutics
7.4.1 Mirati Therapeutics Comapny Information
7.4.2 Mirati Therapeutics Business Overview
7.4.3 Mirati Therapeutics KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Mirati Therapeutics KRAS Inhibitor Product Portfolio
7.4.5 Mirati Therapeutics Recent Developments
7.5 Innovent Biologics
7.5.1 Innovent Biologics Comapny Information
7.5.2 Innovent Biologics Business Overview
7.5.3 Innovent Biologics KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Innovent Biologics KRAS Inhibitor Product Portfolio
7.5.5 Innovent Biologics Recent Developments
7.6 Incyte
7.6.1 Incyte Comapny Information
7.6.2 Incyte Business Overview
7.6.3 Incyte KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Incyte KRAS Inhibitor Product Portfolio
7.6.5 Incyte Recent Developments
7.7 Erasca
7.7.1 Erasca Comapny Information
7.7.2 Erasca Business Overview
7.7.3 Erasca KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Erasca KRAS Inhibitor Product Portfolio
7.7.5 Erasca Recent Developments
7.8 Cardiff Oncology
7.8.1 Cardiff Oncology Comapny Information
7.8.2 Cardiff Oncology Business Overview
7.8.3 Cardiff Oncology KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Cardiff Oncology KRAS Inhibitor Product Portfolio
7.8.5 Cardiff Oncology Recent Developments
7.9 BridgeBio Pharma
7.9.1 BridgeBio Pharma Comapny Information
7.9.2 BridgeBio Pharma Business Overview
7.9.3 BridgeBio Pharma KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 BridgeBio Pharma KRAS Inhibitor Product Portfolio
7.9.5 BridgeBio Pharma Recent Developments
7.10 Boehringer Ingelheim
7.10.1 Boehringer Ingelheim Comapny Information
7.10.2 Boehringer Ingelheim Business Overview
7.10.3 Boehringer Ingelheim KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2020-2025)
7.10.4 Boehringer Ingelheim KRAS Inhibitor Product Portfolio
7.10.5 Boehringer Ingelheim Recent Developments
8 North America
8.1 North America KRAS Inhibitor Market Size by Type
8.1.1 North America KRAS Inhibitor Revenue by Type (2020-2031)
8.1.2 North America KRAS Inhibitor Sales by Type (2020-2031)
8.1.3 North America KRAS Inhibitor Price by Type (2020-2031)
8.2 North America KRAS Inhibitor Market Size by Application
8.2.1 North America KRAS Inhibitor Revenue by Application (2020-2031)
8.2.2 North America KRAS Inhibitor Sales by Application (2020-2031)
8.2.3 North America KRAS Inhibitor Price by Application (2020-2031)
8.3 North America KRAS Inhibitor Market Size by Country
8.3.1 North America KRAS Inhibitor Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
8.3.2 North America KRAS Inhibitor Sales by Country (2020 VS 2024 VS 2031)
8.3.3 North America KRAS Inhibitor Price by Country (2020-2031)
8.3.4 United States
8.3.5 Canada
8.3.6 Mexico
9 Europe
9.1 Europe KRAS Inhibitor Market Size by Type
9.1.1 Europe KRAS Inhibitor Revenue by Type (2020-2031)
9.1.2 Europe KRAS Inhibitor Sales by Type (2020-2031)
9.1.3 Europe KRAS Inhibitor Price by Type (2020-2031)
9.2 Europe KRAS Inhibitor Market Size by Application
9.2.1 Europe KRAS Inhibitor Revenue by Application (2020-2031)
9.2.2 Europe KRAS Inhibitor Sales by Application (2020-2031)
9.2.3 Europe KRAS Inhibitor Price by Application (2020-2031)
9.3 Europe KRAS Inhibitor Market Size by Country
9.3.1 Europe KRAS Inhibitor Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
9.3.2 Europe KRAS Inhibitor Sales by Country (2020 VS 2024 VS 2031)
9.3.3 Europe KRAS Inhibitor Price by Country (2020-2031)
9.3.4 Germany
9.3.5 France
9.3.6 U.K.
9.3.7 Italy
9.3.8 Russia
9.3.9 Spain
9.3.10 Netherlands
10 China
10.1 China KRAS Inhibitor Market Size by Type
10.1.1 China KRAS Inhibitor Revenue by Type (2020-2031)
10.1.2 China KRAS Inhibitor Sales by Type (2020-2031)
10.1.3 China KRAS Inhibitor Price by Type (2020-2031)
10.2 China KRAS Inhibitor Market Size by Application
10.2.1 China KRAS Inhibitor Revenue by Application (2020-2031)
10.2.2 China KRAS Inhibitor Sales by Application (2020-2031)
10.2.3 China KRAS Inhibitor Price by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia KRAS Inhibitor Market Size by Type
11.1.1 Asia KRAS Inhibitor Revenue by Type (2020-2031)
11.1.2 Asia KRAS Inhibitor Sales by Type (2020-2031)
11.1.3 Asia KRAS Inhibitor Price by Type (2020-2031)
11.2 Asia KRAS Inhibitor Market Size by Application
11.2.1 Asia KRAS Inhibitor Revenue by Application (2020-2031)
11.2.2 Asia KRAS Inhibitor Sales by Application (2020-2031)
11.2.3 Asia KRAS Inhibitor Price by Application (2020-2031)
11.3 Asia KRAS Inhibitor Market Size by Country
11.3.1 Asia KRAS Inhibitor Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
11.3.2 Asia KRAS Inhibitor Sales by Country (2020 VS 2024 VS 2031)
11.3.3 Asia KRAS Inhibitor Price by Country (2020-2031)
11.3.4 Japan
11.3.5 South Korea
11.3.6 India
11.3.7 Australia
11.3.8 Taiwan
11.3.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA KRAS Inhibitor Market Size by Type
12.1.1 SAMEA KRAS Inhibitor Revenue by Type (2020-2031)
12.1.2 SAMEA KRAS Inhibitor Sales by Type (2020-2031)
12.1.3 SAMEA KRAS Inhibitor Price by Type (2020-2031)
12.2 SAMEA KRAS Inhibitor Market Size by Application
12.2.1 SAMEA KRAS Inhibitor Revenue by Application (2020-2031)
12.2.2 SAMEA KRAS Inhibitor Sales by Application (2020-2031)
12.2.3 SAMEA KRAS Inhibitor Price by Application (2020-2031)
12.3 SAMEA KRAS Inhibitor Market Size by Country
12.3.1 SAMEA KRAS Inhibitor Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
12.3.2 SAMEA KRAS Inhibitor Sales by Country (2020 VS 2024 VS 2031)
12.3.3 SAMEA KRAS Inhibitor Price by Country (2020-2031)
12.3.4 Brazil
12.3.5 Argentina
12.3.6 Chile
12.3.7 Colombia
12.3.8 Peru
12.3.9 Saudi Arabia
12.3.10 Israel
12.3.11 UAE
12.3.12 Turkey
12.3.13 Iran
12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
13.1 KRAS Inhibitor Value Chain Analysis
13.1.1 KRAS Inhibitor Key Raw Materials
13.1.2 Raw Materials Key Suppliers
13.1.3 Manufacturing Cost Structure
13.1.4 KRAS Inhibitor Production Mode & Process
13.2 KRAS Inhibitor Sales Channels Analysis
13.2.1 Direct Comparison with Distribution Share
13.2.2 KRAS Inhibitor Distributors
13.2.3 KRAS Inhibitor Customers
14 Concluding Insights
15 Appendix
15.1 Reasons for Doing This Study
15.2 Research Methodology
15.3 Research Process
15.4 Authors List of This Report
15.5 Data Source
15.5.1 Secondary Sources
15.5.2 Primary Sources
15.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings